How to Actually Read a Clinical Trial

Beyond the Abstract

In Level 2, we introduced the basics of evaluating research. Now we go deeper. If you want to truly understand what the evidence says about a peptide, you need to be able to read an actual clinical trial — not just the abstract, not just the conclusion, but the methodology, the results tables, and the fine print where the most important information often hides.

This article gives you a practical, section-by-section guide to reading a clinical trial publication. By the end, you will know what to look for, what to question, and where pharmaceutical companies tend to emphasize favorable findings while burying less convenient ones.

Study Design: The Foundation

The first thing to assess is the study design. Key questions:

• Is it randomized? Were participants randomly assigned to treatment or placebo groups? Randomization is the single most important design feature for eliminating bias. Without it, the groups may differ in ways that confound the results.
• Is it controlled? Is there a control group receiving a placebo or an active comparator? A study without a control group cannot distinguish the drug's effect from placebo effect, natural disease progression, or regression to the mean.
• Is it blinded? In a single-blind study, participants do not know whether they are receiving the treatment or placebo. In a double-blind study, neither participants nor investigators know. Blinding prevents expectations from influencing reported outcomes.
• What is the sample size? Larger studies have more statistical power — the ability to detect real differences between groups. Small studies (fewer than 50 participants) can produce misleading results simply due to random variation.
• What is the duration? A 12-week study may not capture effects — positive or negative — that only emerge over longer periods. Always consider whether the study ran long enough to answer the question it claims to answer.

Endpoints: What Is Actually Being Measured?

An endpoint is the outcome a study measures to determine whether the treatment worked. Endpoints are arguably the most important — and most frequently misunderstood — element of a clinical trial.

Primary endpoints are the main outcomes the study was designed to detect. Regulatory agencies like the FDA base their approval decisions primarily on whether a drug achieves its primary endpoint. Secondary endpoints are additional outcomes measured alongside the primary one.

The critical distinction is between surrogate endpoints and clinical endpoints. A surrogate endpoint is a laboratory measurement or biomarker believed to correlate with a clinical outcome — for example, IGF-1 levels as a surrogate for growth hormone activity, or HbA1c as a surrogate for diabetes control. A clinical endpoint is something the patient actually experiences — weight loss, reduced symptom severity, survival time, or quality of life.

Surrogate endpoints are useful for early-stage research, but they can mislead. A drug can improve a biomarker without improving actual health outcomes. When evaluating peptide evidence, always ask: did the study measure something the patient actually experiences, or just a lab value?

Confidence Intervals: The Range of Uncertainty

Every clinical trial result comes with a range of uncertainty expressed as a confidence interval (CI) — typically a 95% CI. If a study reports that a drug produced 15% body weight reduction with a 95% CI of 13% to 17%, this means the researchers are 95% confident that the true effect lies somewhere between 13% and 17%.

Wide confidence intervals indicate less certainty (often due to small sample sizes). Narrow confidence intervals indicate greater precision. If a confidence interval crosses zero (for example, a weight change of -2% with a 95% CI of -5% to +1%), the result is not statistically significant — the true effect could be no effect at all, or even an effect in the opposite direction.

Number Needed to Treat (NNT)

The Number Needed to Treat (NNT) tells you how many people need to receive the treatment for one additional person to benefit compared to the control group. An NNT of 1 would mean every treated person benefits (essentially impossible for most drugs). An NNT of 10 means you need to treat 10 people for one additional person to see the benefit beyond what the placebo group experienced.

NNT puts efficacy into practical perspective. A drug might achieve statistical significance (p < 0.05) while having an NNT of 100 — meaning for every 100 people treated, only one additional person benefits. That changes how you think about the drug's value, particularly if it has notable side effects or high cost.

What Pharma Companies Tend to Emphasize — and What They Downplay

Clinical trials are expensive, and the companies that fund them have a financial interest in presenting the results favorably. This does not mean the data is fabricated — FDA scrutiny makes outright fraud rare — but presentation matters. Common patterns:

• Relative risk reduction vs. absolute risk reduction. Reporting that a drug "reduces the risk by 50%" sounds impressive. But if the baseline risk was 2% and the drug reduced it to 1%, the absolute risk reduction is only 1 percentage point. The relative framing makes the same result sound much more dramatic.
• Subgroup analyses. When the overall result is underwhelming, sponsors may highlight a subgroup where the drug performed better — "in patients over 65, the drug showed a 20% greater effect." Subgroup analyses are hypothesis-generating, not confirmatory, and are vulnerable to cherry-picking.
• Per-protocol vs. intention-to-treat analysis. Per-protocol analysis only includes participants who completed the study as designed. Intention-to-treat analysis includes everyone who was randomized, even if they dropped out. Intention-to-treat is more conservative and more honest — if many participants dropped out due to side effects, per-protocol analysis hides that attrition.
• Composite endpoints. Combining multiple outcomes into a single "composite endpoint" can make a drug appear more effective by allowing a win on any of several measures, even if it failed on the one that matters most to patients.

The Washout Period

Some studies include a washout period — a phase before the trial begins where participants stop all relevant medications to establish a true baseline. This matters because residual effects from prior treatments can confound results. When reading a trial, check whether a washout was included and whether it was long enough for prior drugs to be fully cleared (typically 5 or more half-lives).

Putting It Into Practice

You do not need to become a biostatistician. But the next time you see a claim about a peptide supported by "clinical data," pull up the actual study and look at: the design (RCT or not?), the sample size, the primary endpoint (surrogate or clinical?), the confidence intervals, and the funding source. These five elements will tell you more about the reliability of the findings than any marketing summary ever will.

This article is for educational purposes only and does not constitute medical advice.

Next up: advanced pharmacokinetics — the mathematical relationships between dose, concentration, and effect that underpin rational dosing decisions.